We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y
Read MoreHide Full Article
Key Takeaways
Mettler-Toledo's Q3 earnings of $11.15 per share beat estimates and rose 9.2% year over year.
Net sales of $1.03B topped expectations, with growth across Laboratory, Industrial and Food Retail units.
The company projects steady sales and earnings growth through 2026, supported by solid segment trends.
Mettler-Toledo International (MTD - Free Report) reported third-quarter 2025 adjusted earnings of $11.15 per share, which beat the Zacks Consensus Estimate by 4.99%. The bottom line increased 9.2% on a year-over-year basis.
Net sales of $1.03 billion surpassed the Zacks Consensus Estimate by 3.84%. The figure declined 8% on a reported basis and 6% on a local currency basis from the year-ago quarter.
MTD’s Q3 Top Line in Detail
MTD reports revenues under three segments, namely Laboratory, Industrial and Food Retail, which generated sales of $565 million (54.9% of the net sales), $406 million (39.4% of the net sales) and $59 million (5.7% of the net sales), respectively, in the third quarter. The Laboratory, Industrial, and Food Retail segments witnessed year-over-year growth of 4%, 9%, and 5% respectively, on a local currency basis.
Total sales from the Americas, Europe and Asia/Rest of the World were $432 million (41.9% of the net sales), $293 million (28.4%) and $305 million (29.6%), respectively. Sales in the Americas and Asia / Rest of the World increased 4% and 1% year over year, respectively, on a local currency basis. Meanwhile, Europe sales were unchanged year over year.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
In the third quarter of 2025, the gross margin was 59.2%, which contracted 80 basis points (bps) year over year.
Research & development (“R&D”) expenses were $51.1 million, up 8.5% year over year. Selling, general & administrative (“SG&A”) expenses increased 8.6% year over year to $248.4 million. As a percentage of sales, R&D expenses increased 20 bps year over year. SG&A expenses increased 220 bps year over year as a percentage of sales.
The adjusted operating margin was 30.1%, which declined 100 bps year over year.
MTD’s Balance Sheet & Cash Flow
As of Sept. 30, 2025, Mettler-Toledo’s cash and cash-equivalent balance was $69.1 million, up from $61.8 million as of June 30. The long-term debt was $2.15 billion as of Sept. 30, 2025.
Mettler-Toledo generated $299.4 million in cash from operating activities in the reported quarter. The free cash flow was $280.7 million in the reported quarter.
Mettler-Toledo’s Q4 & 2025 Guidance
For the fourth quarter of 2025, Mettler-Toledo anticipates sales to increase roughly 3% in local currency year over year.
Adjusted earnings are anticipated to be between $12.68 per share and $12.88 per share, a growth rate of 2% to 4% year over year.
For 2025, Mettler-Toledo anticipates sales in local currency to increase approximately 2% over 2024. The company expects adjusted earnings between $42.05 per share and $42.25 per share, representing 2-3% growth over 2024.
For 2026, Mettler-Toledo anticipates sales in local currency to increase approximately 4%, over 2025. The company expects adjusted earnings between $45.35 per share and $46.00 per share, indicating 8-9% growth over 2025.
Zacks Rank & Stocks to Consider
Currently, Mettler-Toledo has a Zacks Rank #3 (Hold).
ADC Therapeutics (ADCT - Free Report) , Akebia Therapeutics (AKBA - Free Report) and Alcon (ALC - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
Akebia Therapeutics shares have returned 5.7% year to date. Akebia Therapeutics is scheduled to release third-quarter 2025 results on Nov. 10. Akebia Therapeutics has a Zacks Rank #2.
Alcon shares have dropped 12.5% year to date. Alcon is set to report its third-quarter 2025 results on Nov. 12. Alcon currently has a Zacks Rank #2.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y
Key Takeaways
Mettler-Toledo International (MTD - Free Report) reported third-quarter 2025 adjusted earnings of $11.15 per share, which beat the Zacks Consensus Estimate by 4.99%. The bottom line increased 9.2% on a year-over-year basis.
Net sales of $1.03 billion surpassed the Zacks Consensus Estimate by 3.84%. The figure declined 8% on a reported basis and 6% on a local currency basis from the year-ago quarter.
MTD’s Q3 Top Line in Detail
MTD reports revenues under three segments, namely Laboratory, Industrial and Food Retail, which generated sales of $565 million (54.9% of the net sales), $406 million (39.4% of the net sales) and $59 million (5.7% of the net sales), respectively, in the third quarter. The Laboratory, Industrial, and Food Retail segments witnessed year-over-year growth of 4%, 9%, and 5% respectively, on a local currency basis.
Total sales from the Americas, Europe and Asia/Rest of the World were $432 million (41.9% of the net sales), $293 million (28.4%) and $305 million (29.6%), respectively. Sales in the Americas and Asia / Rest of the World increased 4% and 1% year over year, respectively, on a local currency basis. Meanwhile, Europe sales were unchanged year over year.
Mettler-Toledo International, Inc. Price, Consensus and EPS Surprise
Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Toledo International, Inc. Quote
Mettler-Toledo’s Q3 Operating Details
In the third quarter of 2025, the gross margin was 59.2%, which contracted 80 basis points (bps) year over year.
Research & development (“R&D”) expenses were $51.1 million, up 8.5% year over year. Selling, general & administrative (“SG&A”) expenses increased 8.6% year over year to $248.4 million. As a percentage of sales, R&D expenses increased 20 bps year over year. SG&A expenses increased 220 bps year over year as a percentage of sales.
The adjusted operating margin was 30.1%, which declined 100 bps year over year.
MTD’s Balance Sheet & Cash Flow
As of Sept. 30, 2025, Mettler-Toledo’s cash and cash-equivalent balance was $69.1 million, up from $61.8 million as of June 30. The long-term debt was $2.15 billion as of Sept. 30, 2025.
Mettler-Toledo generated $299.4 million in cash from operating activities in the reported quarter. The free cash flow was $280.7 million in the reported quarter.
Mettler-Toledo’s Q4 & 2025 Guidance
For the fourth quarter of 2025, Mettler-Toledo anticipates sales to increase roughly 3% in local currency year over year.
Adjusted earnings are anticipated to be between $12.68 per share and $12.88 per share, a growth rate of 2% to 4% year over year.
For 2025, Mettler-Toledo anticipates sales in local currency to increase approximately 2% over 2024. The company expects adjusted earnings between $42.05 per share and $42.25 per share, representing 2-3% growth over 2024.
For 2026, Mettler-Toledo anticipates sales in local currency to increase approximately 4%, over 2025. The company expects adjusted earnings between $45.35 per share and $46.00 per share, indicating 8-9% growth over 2025.
Zacks Rank & Stocks to Consider
Currently, Mettler-Toledo has a Zacks Rank #3 (Hold).
ADC Therapeutics (ADCT - Free Report) , Akebia Therapeutics (AKBA - Free Report) and Alcon (ALC - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector.
ADC Therapeutics shares have appreciated 109.1% year to date. This Zacks Rank #2 (Buy) company is scheduled to release third-quarter 2025 results on Nov. 10. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Akebia Therapeutics shares have returned 5.7% year to date. Akebia Therapeutics is scheduled to release third-quarter 2025 results on Nov. 10. Akebia Therapeutics has a Zacks Rank #2.
Alcon shares have dropped 12.5% year to date. Alcon is set to report its third-quarter 2025 results on Nov. 12. Alcon currently has a Zacks Rank #2.